Comorbidity of alcohol dependence with other psychiatric disorders. Part II. Pathogenesis and treatment;Współwystępowanie uzależnienia od alkoholu z innymi zaburzeniami psychicznymi. Czę̈ć II. Patogeneza i leczenie

Psychiatria Polska

Volumn 49, Issue 2, 2015, Pages 277-294

  Klimkiewicz, Anna ^a   Klimkiewicz, Jakub ^b   Jakubczyk, Andrzej ^a   Kieres Salomoński, Ilona ^a,c,d   Wojnar, Marcin ^a,e  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b Klinika Anestezjologii i Intensywnej Terapii Wojskowego Instytutu Medycznego w Warszawie   (Poland)

^c Centralne Biuro ͆ledcze ^*  (Poland)

^d Zespó ds Prekursorów Narkotykowych Radzie ds Przeciwdzia ania Narkomanii   (Poland)

^e UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Alcohol dependence; Dual diagnosis; Mental disorders; Pathophysiology; Treatment

Indexed keywords

ALCOHOLISM; ANXIETY DISORDER; ARTICLE; COMORBIDITY; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MENTAL DISEASE; MENTAL HEALTH CARE; MOOD DISORDER; PATHOGENESIS; ANXIETY DISORDERS; BEHAVIOR, ADDICTIVE; HEALTH STATUS; HUMANS; MENTAL DISORDERS; MOOD DISORDERS; PANIC DISORDER; PREVALENCE; RISK FACTORS;

ALCOHOLISM; ANXIETY DISORDERS; BEHAVIOR, ADDICTIVE; COMORBIDITY; HEALTH STATUS; HUMANS; MENTAL DISORDERS; MOOD DISORDERS; PANIC DISORDER; PREVALENCE; RISK FACTORS;

EID: 84928782145     PISSN: 00332674     EISSN: None     Source Type: Journal    
DOI: 10.12740/PP/26071     Document Type: Article

References (82)

1. Anthenelli RM. A basic clinical approach to diagnosis in patients with comorbid psychiatric and substance use disorders. W: Miller NS. red. Principles and practice of addictions in psychiatry. Philadelphia, PA: W.B. Saunders Company; 1997. s. 119-126.
2. Modesto-Lowe V, Kranzler HR. Diagnosis and treatment of alcohol-dependent patients with comorbid psychiatric disorders. Alcohol Res. Health 1999; 23(2): 144-149.
3. Błachut M, Badura-Brzoza K, Jarzab M, Gorczyca P, Hese RT. Podwójna diagnoza u osób uzależnionych lub szkodliwie używających substancji psychoaktywnych. Psychiatr. Pol. 2013; 47(2): 335-352.
4. Anthenelli RM, Schuckit MA. Affective and anxiety disorders and alcohol and drug dependence: diagnosis and treatment. J. Addict. Dis. 1993; 12(3): 73-87.
5. Brown SA, Irwin M, Schuckit MA. Changes in anxiety among abstinent male alcoholics. J. Stud. Alcohol. 1991; 52(1): 55-61.
6. Brown SA, Inaba RK, Gillin JC, Schuckit MA, Stewart MA, Irwin MR. Alcoholism and affective disorder: clinical course of depressive symptoms. Am. J. Psychiatry 1995; 152(1): 45-52.
7. Department of Health. Mental Health Policy Implementation Guide: Dual diagnosis good practice. London: Crown Copyright; 2002.
8. Lesch OM, Walter H. Subtypes of alcoholism and their role in therapy. Alcohol Alcohol. Suppl. 1996; 31(1): 63-67.
9. Petrakis I, Gonzalez G, Rosenheck R, Krystal J. Comorbidity of alcoholism and psychiatric disorders. An overview. http://pubs.niaaa.nih.gov/publications/arh26-2/81-89.htm [dostęp: 06.03.2015].
10. Helzer JE, Pryzbeck TR. The co-occurrence of alcoholism with other psychiatric disorders in the general population and its impact on treatment. J. Stud. Alcohol. 1988; 49(3): 219-224.
11. Anthenelli RM. Sex differences in the stress hormone response to the combined dexamethasone-corticotropin-releasing hormone (Dex-CRH) stimulation test. San Diego, California: Alcohol Stress Interest Group, 32nd Annual Scientific Meeting of the Research Society on Alcoholism; 2009.
12. Heilig M, Koob GF. A key role for corticotropin-releasing factor in alcohol dependence. Trends Neurosci. 2007; 30(8): 399-406.
13. Adinoff B, Junghanns K, Kiefer F, Krishnan-Sarin S. Suppression of the HPA axis stress-response: implications for relapse. Alcohol. Clin. Exp. Res. 2005; 29(7): 1351-1355.
14. Ulrich-Lai YM, Herman JP. Neural regulation of endocrine and autonomic stress responses. Nat. Rev. Neurosci. 2009; 10(6): 397-409.
15. Koob GF, Le Moal M. Plasticity of reward neurocircuitry and the 'dark side' of drug addiction. Nat. Neurosci. 2005; 8(11): 1442-1444.
16. Koob GF. Brain stress systems in the amygdala and addiction. Brain Res. 2009; 1293: 61-75.
17. Richardson HN, Lee SY, O'Dell LE, Koob GF, Rivier CL. Alcohol self-administration acutely stimulates the hypothalamic-pituitary-adrenal axis, but alcohol dependence leads to a dampened neuroendocrine state. Eur. J. Neurosci. 2008; 28(8): 1641-1653.
18. Kudielka BM, Hellhammer DH, Wust S. Why do we respond so differently? Reviewing determinants of human salivary cortisol responses to challenge. Psychoneuroendocrinol. 2009; 34(1): 2-18.
19. Koob GF, Le Moal M. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 2001; 24(2): 97-129.
20. Junghanns K, Backhaus J, Tietz U, Lange W, Bernzen J, Wetterling T. i wsp. Impaired serum cortisol stress response is a predictor of early relapse. Alcohol Alcohol. 2003; 38(2): 189-193.
21. McEwen BS, Wingfield JC. What is in a name? Integrating homeostasis, allostasis and stress. Horm. Behav. 2010; 57(2): 105-111.
22. Shivani RG, Goldsmith RJ, Anthenelli RM. Alcoholism and psychiatric disorders: Diagnostic challenges. Alcohol Res. Health 2002; 26: 90-98.
23. Handwerger K. Differential patterns of HPA activity and reactivity in adult posttraumatic stress disorder and major depressive disorder. Harv. Rev. Psychiatry 2009; 17(3): 184-205.
24. Shea A, Walsh C, Macmillan H, Steiner M. Child maltreatment and HPA axis dysregulation: relationship to major depressive disorder and post traumatic stress disorder in females. Psychoneuroendocrinology 2005; 30(2): 162-178.
25. Ehlert U, Gaab J, Heinrichs M. Psychoneuroendocrinological contributions to the etiology of depression, posttraumatic stress disorder, and stress-related bodily disorders: the role of the hypothalamus-pituitary-adrenal axis. Biol. Psychol. 2001; 57(1-3): 141-152.
26. Yehuda R. Status of glucocorticoid alterations in post-traumatic stress disorder. Ann. N. Y. Acad. Sci. 2009; 1179: 56-69.
27. Volpicelli J, Balaraman G, Hahn J, Wallace H, Bux D. The role of uncontrollable trauma in the development of PTSD and alcohol addiction. Alcohol Res. Health 1999; 23(4): 256-262.
28. Brady KT, Back SE, Waldrop AE, McRae AL, Anton RF, Upadhyaya HP. i wsp. Cold pressor task reactivity: predictors of alcohol use among alcohol-dependent individuals with and without comorbid posttraumatic stress disorder. Alcohol. Clin. Exp. Res. 2006; 30(6): 938-946.
29. Brady KT, Waldrop AE, McRae AL, Back SE, Saladin ME, Upadhyaya HP. i wsp. The impact of alcohol dependence and posttraumatic stress disorder on cold pressor task response. J. Stud. Alcohol. 2006; 67(5): 700-706.
30. Fox HC, Sinha R. Sex differences in drug-related stress-system changes: implications for treatment in substance-abusing women. Harv. Rev. Psychiatry 2009; 17(2): 103-119.
31. Witt ED. Puberty, hormones, and sex differences in alcohol abuse and dependence. Neurotoxicol. Teratol. 2007; 29(1): 81-95.
32. Kajantie E, Phillips DI. The effects of sex and hormonal status on the physiological response to acute psychosocial stress. Psychoneuroendocrinology 2006; 31(2): 151-178.
33. Kirschbaum C, Kudielka BM, Gaab J, Schommer NC, Hellhammer DH. Impact of gender, menstrual cycle phase, and oral contraceptives on the activity of the hypothalamus-pituitaryadrenal axis. Psychosom. Med. 1999; 61(2): 154-162.
34. Anthenelli RM, Maxwell RA, Geracioti TD Jr, Hauger R. Stress hormone dysregulation at rest and after serotonergic stimulation among alcohol-dependent men with extended abstinence and controls. Alcohol. Clin. Exp. Res. 2001; 25(5): 692-703.
35. Ogilvie KM, Rivier C. Gender difference in hypothalamic-pituitary-adrenal axis response to alcohol in the rat: activational role of gonadal steroids. Brain Res. 1997; 766(1-2): 19-28.
36. Larkin JW, Binks SL, Li Y, Selvage D. The role of oestradiol in sexually dimorphic hypothalamic-pituitary-adrenal axis responses to intracerebroventricular ethanol administration in the rat. J. Neuroendocrinol. 2010; 22(1): 24-32.
37. Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H. i wsp. Use of mental health services in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr. Scand. Suppl. 2004; 420: 47-54.
38. Wu LT, Kouzis AC, Leaf PJ. Influence of comorbid alcohol and psychiatric disorders on utilization of mental health services in the National Comorbidity Survey. Am. J. Psychiatry 1999; 156(8): 1230-1236.
39. Holder HD, Blose JO. A comparison of occupational and nonoccupational disability payments and work absences for alcoholics and nonalcoholics. J. Occup. Med.1991; 33(4): 453-457.
40. Holder HD, Blose JO. The reduction of health care costs associated with alcoholism treatment: a 14-year longitudinal study. J. Stud. Alcohol. 1992; 53(4): 293-302
41. Blose JO, Holder HD. The utilization of medical care by treated alcoholics: longitudinal patterns by age, gender, and type of care. J. Subst. Abuse 1991; 3(1): 13-27.
42. Holder HD, Blose JO. Typical patterns and cost of alcoholism treatment across a variety of populations and providers. Alcohol. Clin. Exp. Res. 1991; 15(2): 190-195.
43. Meyer RE. Prospects for a rational pharmacotherapy of alcoholism. J. Clin. Psychiatry 1989; 50(11): 403-412.
44. Fuller RK, Branchey L, Brightwell DR, Derman RM, Emrick CD, Iber FL. i wsp. Disulfiram treatment of alcoholism. A Veterans Administration cooperative study. JAMA 1986; 256(11): 1449-1455.
45. Chick J. Safety issues concerning the use of disulfiram in treating alcohol dependence. Drug Saf. 1999; 20(5): 427-435.
46. Chick J, Gough K, Falkowski W, Kershaw P, Hore B, Mehta B. i wsp. Disulfiram treatment of alcoholism. Br. J. Psychiatry 1992; 161: 84-89.
47. O'Farrell TJ, Bayog RD. Antabuse contracts for married alcoholics and their spouses: a method to maintain antabuse ingestion and decrease conflict about drinking. J. Subst. Abuse Treat. 1986; 3(1): 1-8.
48. Larson EW, Olincy A, Rummans TA, Morse RM. Disulfiram treatment of patients with both alcohol dependence and other psychiatric disorders: a review. Alcohol. Clin. Exp. Res. 1992; 16(1): 125-130.
49. Kofoed L, Kania J, Walsh T, Atkinson RM. Outpatient treatment of patients with substance abuse and coexisting psychiatric disorders. Am. J. Psychiatry 1986; 143(7): 867-872.
50. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. Arch. Gen. Psychiatry 1992; 49(11): 876-880.
51. O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch. Gen. Psychiatry 1992; 49(11): 881-887.
52. Anton RF, Moak DH, Waid LR, Latham PK, Malcolm RJ, Dias JK. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am. J. Psychiatry 1999; 156(11): 1758-1764.
53. Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA, Veterans Affairs Naltrexone Cooperative Study 425 Group. Naltrexone in the treatment of alcohol dependence. N. Engl. J. Med. 2001; 345(24): 1734-1739.
54. Sernyak MJ, Glazer WM, Heninger GR, Charney DS, Woods SW, Petrakis IL. i wsp. Naltrexone augmentation of neuroleptics in schizophrenia. J. Clin. Psychopharmacol. 1998; 18(3): 248-251.
55. Croop RS, Faulkner EB, Labriola DF. The safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study. The Naltrexone Usage Study Group. Arch. Gen. Psych. 1997; 54(12): 1130-1135.
56. Maxwell S, Shinderman MS. Use of naltrexone in the treatment of alcohol use disorders in patients with concomitant major mental illness. J. Addict. Dis. 2000; 19(3): 61-69.
57. Mason BJ, Ownby RL. Acamprosate for the treatment of alcohol dependence: a review of double-blind, placebo-controlled trials. CNS Spectr. 2000; 5(2): 58-69.
58. Keating GM. Nalmefene: a review of its use in the treatment of alcohol dependence. CNS Drugs 2013; 27(9): 761-772.
59. Pettinati HM, Oslin D, Decker K. Role of serotonin and serotonin-selective pharmacotherapy in alcohol dependence. CNS Spectr. 2000; 5(2): 33-46.
60. Kranzler H, Rounsaville B. red. Dual diagnosis and treatment. New York: Marcel Dekker; 1998.
61. Berman RM, Charney DS. Models of antidepressant action. J. Clin. Psychiatry 1999; 60(supl. 14):16-20.
62. Habrat B, Załoga B. Skutecznöć i tolerancja tianeptyny w leczeniu zaburzeń depresyjnych u pacjentów uzależnionych od alkoholu. Wieloörodkowe badanie kontrolowane metodą podwójnie ̈lepej próby z użyciem fluwoksaminy. Psychiatr. Pol. 2006; 40(3): 579-597.
63. Cornelius JR, Salloum IM, Ehler JG, Jarrett PJ, Cornelius MD, Perel JM. i wsp. Fluoxetine in depressed alcoholics. A double-blind, placebo-controlled trial. Arch. Gen. Psychiatry 1997; 54(8): 700-705.
64. Cornelius JR, Salloum IM, Thase ME, Haskett RF, Daley DC, Jones-Barlock A. i wsp. Fluoxetine versus placebo in depressed alcoholic cocaine abusers. Psychopharmacol. Bull. 1998; 34(1): 117-121.
65. Sellers EM, Toneatto T, Romach MK, Somer GR, Sobell LC, Sobell MB. Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence. Alcohol. Clin. Exp. Res. 1994; 18(4): 879-885.
66. Pettinati HM, Volpicelli JR, Kranzler HR, Luck G, Rukstalis MR, Cnaan A. Sertraline treatment for alcohol dependence: interactive effects of medication and alcoholic subtype. Alcohol. Clin. Exp. Res. 2000; 24(7): 1041-1049.
67. Brady KT, Sonne SC, Roberts JM. Sertraline treatment of comorbid posttraumatic stress disorder and alcohol dependence. J. Clin. Psychiatry 1995; 56(11): 502-505.
68. Myrick H, Brady KT, Malcolm R. New developments in the pharmacotherapy of alcohol dependence. Am. J. Addict. 2001; 10(supl.): 3-15.
69. Drake RE, Xie H, McHugo GJ, Green AI. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr. Bull. 2000; 26(2): 441-449.
70. Murthy P, Chand P. Treatment of dual diagnosis disorders. Curr. Opin. Psychiatry 2012; 25(3): 194-200.
71. Frye MA, Salloum IM. Bipolar disorder and comorbid alcoholism: prevalence rate and treatment considerations. Bipolar Disord. 2006: 8: 677-685.
72. Sonne SC, Brady KT. Bipolar disorder and alcoholism. http://pubs.niaaa.nih.gov/publications/arh26-2/103-108.htm [dostęp: 1.04.2014].
73. Sonne SC, Brady KT. Safety of Depakote in bipolar patients with comorbid alcohol abuse/dependence. Am. J. Psychiatry 1999; 156: 1122.
74. Salloum IM, Cornelius JR, Daley DC, Kirisci L, Himmelhoch JM, Thase ME. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study. Arch. Gen. Psychiatry 2005; 62(1): 37-45.
75. Bonnet U, Schäfer M, Richter C, Milkereit J, Wiltfang J, Scherbaum N. i wsp. Anticonvulsants in the treatment of alcoholism. Fortschr. Neurol. Psychiatr. 2009; 77(4): 192-202.
76. Malcolm R, Myrick H, Roberts J, Wang W, Anton RF, Ballenger JC. The effects of carbamazepine and lorazepam on single versus multiple previous alcohol withdrawals in an outpatient randomized trial. J. Gen. Intern. Med. 2002; 17: 349-355.
77. Mueller TI, Stout RL, Rudden S, Brown RA, Gordon A, Solomon DA. i wsp. A double-blind, placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence. Alcohol. Clin. Exp. Res. 1997; 21: 86-92.
78. Prisciandaro JJ, Brown DG, Brady KT, Tolliver BK. Comorbid anxiety disorders and baseline medication regimens predict clinical outcomes in individuals with co-occurring bipolar disorder and alcohol dependence: Results of a randomized controlled trial. Psychiatry 2011; 188(3): 361-365.
79. Hutchison KE, Swift R, Rohsenow DJ, Monti PM, Davidson D, Almeida A. Olanzapine reduces urge to drink after drinking cues and a priming dose of alcohol. Psychopharmacology (Berl.) 2001; 155: 27-34.
80. Spiridonow K, Orzechowska Z. Kompetencje społeczne osób z podwójną diagnozą - przegląd literatury. Psychiatr. Pol. 2007; 41(1): 53-61.
81. Habrat B, Bidzińska E. Adaptacja socjalna u osób z chorobą afektywną dwubiegunową w zależnöci od występowania problemów alkoholowych (badania pilotażowe). Psychiatr. Pol. 1991; 25(1): 21-28
82. Kandel I. Program terapeutyczny dla pacjentów z podwójną diagnozą, nadużywających substancji psychoaktywnych. Psychiatr. Pol. 2007; 41(5): 727-736.